Kiniksa Pharmaceuticals International, plc Logo

Kiniksa Pharmaceuticals International, plc

Develops immune-modulating therapies for autoimmune and cardiovascular diseases.

KNSA | US

Overview

Corporate Details

ISIN(s):
BMG5269C1010
LEI:
Country:
United States of America
Address:
23 OLD BOND STREET, FLOOR 3, LONDON

Description

Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic medicines for patients with debilitating diseases and significant unmet medical needs. The company's portfolio is centered on immune-modulating assets. Its commercial product, ARCALYST® (rilonacept), is an interleukin-1α and interleukin-1β cytokine trap for the treatment of recurrent pericarditis and other autoinflammatory diseases. Kiniksa's clinical development pipeline includes investigational therapies such as KPL-387, a monoclonal antibody IL-1 receptor antagonist also being evaluated for recurrent pericarditis. The company concentrates its efforts in therapeutic areas including cardiovascular and autoimmune diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kiniksa Pharmaceuticals International, plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kiniksa Pharmaceuticals International, plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kiniksa Pharmaceuticals International, plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

BELITE BIO, INC Logo
Clinical-stage biopharma developing therapies for retinal and metabolic diseases.
United States of America
BLTE
Benitec Biopharma Inc. Logo
A clinical-stage biotech developing genetic medicines to silence disease-causing genes.
United States of America
BNTC
BeOne Medicines Ltd. Logo
Global oncology company that discovers, develops, and delivers cancer treatments.
United States of America
ONC
BerGenBio Logo
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
Norway
BGBIO
Beximco Pharmaceuticals Ltd. Logo
Manufacturer of generic drugs, APIs, and specialized products for global markets.
Bangladesh
BXP
BeyondSpring Inc. Logo
Clinical-stage biopharma company developing immuno-oncology cancer therapies.
United States of America
BYSI
BGM Group Ltd. Logo
A holding company focused on technology and biopharmaceutical manufacturing.
United States of America
BGM
Bicara Therapeutics Inc. Logo
Clinical-stage biopharma developing dual-action biologics for solid tumors.
United States of America
BCAX
BICYCLE THERAPEUTICS PLC Logo
Clinical-stage biopharma developing a novel class of bicyclic peptide medicines.
United States of America
BCYC
BIFIDO. Co. Ltd Logo
Biotechnology firm developing human-derived Bifidobacterium for various products.
South Korea
238200

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.